Opinion|Videos|September 2, 2024
Changing Standard of Care in Atopic Dermatitis
The panel provides comprehensive insights on treating atopic dermatitis and how recent advances have elevated standard-of-care treatment practices in dermatology practices.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Recent treatment advances are providing greater improvement in itch, clearing of skin, etc.
- Have these advances led to elevation of standard of care in dermatology practices?
- Have these advances led to elevation of standard of care in dermatology practices?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5